Printed from Voxsanity (voxsanity.com.au) — NCT06900075 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Type 2 Diabetes
Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting
NCT06900075
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 to 75 years old (inclusive) at the time of screening, of any gender.
- People who have been diagnosed with Type 2 Diabetes for at least 8 weeks before screening, and who have not taken any diabetes medications in the 8 weeks before screening.
- People whose HbA1c (a blood sugar measurement taken over several months) is between 7.5% and 11.0% at screening.
- People whose fasting blood sugar level is 13.9 mmol/L or lower at screening.
- People whose Body Mass Index (BMI) — a measure of body weight relative to height — is between 19.0 and 35.0 kg/m² (inclusive) at screening.
- People who are able to understand the purpose of the study, are willing to take part and receive the relevant treatments, and are able to provide written consent to participate.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have Type 1 diabetes or another specific type of diabetes (other than Type 2).
- People who have taken any diabetes medications (including herbal medicines, traditional medicines, or health products) in the 2 months before screening.
- People who have taken certain non-diabetes medications that can significantly affect blood sugar levels for 7 or more days within 2 months before screening — these include some steroid medicines (such as cortisone-type tablets or injections, but not inhaled, eye drop, or skin-applied forms), growth hormones, certain heart or nerve medicines, high-dose aspirin (over 300 mg per day), danazol, octreotide, or certain hormone-related medicines (confirm with trial site for the full list).
- People who have a known allergy or sensitivity to a class of diabetes medicines called GLP-1 receptor agonists.
- People who have had a serious diabetes-related emergency (such as diabetic ketoacidosis or a dangerous high blood sugar episode) in the 6 months before screening.
- People who have had certain serious diabetes complications in the 6 months before screening, including severe eye problems affecting vision, severe nerve damage, poor circulation in the legs, or diabetic foot disease requiring treatment.
- People who have had a severe low blood sugar episode in the 6 months before screening, or three or more non-severe low blood sugar episodes in the month before screening.
- People who have a history of delayed stomach emptying (gastroparesis), clinically significant stomach-emptying problems, or serious digestive tract disease.
- People who have a condition that may affect the reliability of the HbA1c blood test, such as certain blood cancers, a type of anaemia where red blood cells break down too quickly, or sickle cell disease.
- People who have a history of inflammation of the pancreas (pancreatitis), either short-term or long-term.
- People who have had an acute gallbladder inflammation in the 6 months before screening, or gallstones causing symptoms or requiring treatment in the 6 months before screening (except people who have had their gallbladder removed and are stable).
- People who have Cushing's syndrome, an overactive thyroid, or a poorly controlled underactive thyroid at screening (some exceptions may apply — confirm with trial site).
- People who have a personal or close family history (in a parent, sibling, or child) of a condition called multiple endocrine neoplasia type 2 or medullary thyroid cancer.
- People who have had certain serious heart or stroke-related events in the 6 months before screening, including severe heart failure, an abnormal heart rhythm requiring treatment, unstable chest pain, a heart attack, heart bypass surgery or a stent procedure, stroke, or a mini-stroke (transient ischaemic attack).
- People who have had a cancer diagnosis in the past 5 years (with the possible exception of certain fully treated early-stage cancers — confirm with trial site), or who are currently being investigated for a possible cancer.
- People who have had a serious injury, serious infection, or surgery that may affect blood sugar control in the month before screening, or who have planned surgery that may interfere with completing the study.
- People whose blood pressure at screening is 160 mmHg (systolic) or higher and/or 100 mmHg (diastolic) or higher.
- People who have a clinically significant abnormality on their heart tracing (ECG) that may affect their safety or the study results.
- People whose liver enzyme levels (ALT or AST) or bilirubin levels in their blood are significantly above the normal range at screening (confirm specific thresholds with trial site).
- People whose kidney filtration rate (eGFR) is below 60 mL/min/1.73 m², indicating reduced kidney function.
- People with a serum calcitonin level (a hormone measured in the blood) of 50 ng/L or above at screening.
- People whose haemoglobin (a measure of red blood cells) is below 100 g/L at screening.
- People with very high fasting triglyceride (blood fat) levels of 5.7 mmol/L or above at screening.
- People with significantly elevated levels of pancreatic enzymes (amylase and/or lipase) in their blood at screening.
- People who test positive for HIV, hepatitis C, syphilis, or certain hepatitis B markers at screening.
- People who have received a blood or plasma transfusion in the 3 months before screening, or who have donated blood or lost more than 400 mL of blood in the 3 months before screening.
- People with a known or suspected history of excessive alcohol use in the past year, defined as drinking more than 14 units of alcohol per week (where 1 unit is approximately 360 mL of beer, 150 mL of wine, or 45 mL of spirits).
- People with a history of drug abuse or dependence on substances.
- Women who are pregnant or breastfeeding at screening, or who have a positive pregnancy test.
- People of childbearing potential (or male participants whose female partners could become pregnant) who plan to conceive from the time of signing the consent form until 3 months after the last dose, or who are unwilling to use effective contraception during this period.
- People who have taken part in another clinical trial involving an investigational (unapproved) medicine within 3 months before screening.
- People who the trial doctor considers unsuitable to participate for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: +86 13910978815
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Registry
ClinicalTrials.gov
Start date
30 July 2025
Est. completion
30 January 2026
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Time in range (TIR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.